Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LH 
Laboratory Corporation of America Holdings (LH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: LH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $300
1 Year Target Price $300
| 13 | Strong Buy |
| 3 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 8.56% | Avg. Invested days 48 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 23.60B USD | Price to earnings Ratio 31.35 | 1Y Target Price 300 |
Price to earnings Ratio 31.35 | 1Y Target Price 300 | ||
Volume (30-day avg) 20 | Beta 0.87 | 52 Weeks Range 208.23 - 293.72 | Updated Date 10/24/2025 |
52 Weeks Range 208.23 - 293.72 | Updated Date 10/24/2025 | ||
Dividends yield (FY) 1.02% | Basic EPS (TTM) 9.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-23 | When Before Market | Estimate 4.11 | Actual - |
Profitability
Profit Margin 5.66% | Operating Margin (TTM) 11.3% |
Management Effectiveness
Return on Assets (TTM) 4.44% | Return on Equity (TTM) 9.26% |
Valuation
Trailing PE 31.35 | Forward PE 15.8 | Enterprise Value 29120164000 | Price to Sales(TTM) 1.75 |
Enterprise Value 29120164000 | Price to Sales(TTM) 1.75 | ||
Enterprise Value to Revenue 2.16 | Enterprise Value to EBITDA 15.57 | Shares Outstanding 83100000 | Shares Floating 82662063 |
Shares Outstanding 83100000 | Shares Floating 82662063 | ||
Percent Insiders 0.34 | Percent Institutions 100.19 |
Upturn AI SWOT
Laboratory Corporation of America Holdings
Company Overview
History and Background
Laboratory Corporation of America Holdings (Labcorp) was founded in 1978 as Roche Biomedical Laboratories. It evolved through acquisitions and organic growth to become a leading global life sciences company, providing diagnostic and drug development services.
Core Business Areas
- Diagnostics: Offers a broad range of routine and specialty testing services to physicians, hospitals, managed care organizations, and other clinical laboratories.
- Drug Development: Provides preclinical and clinical trial services to pharmaceutical and biotechnology companies, including central laboratory services, clinical trial management, and bioanalytical testing.
Leadership and Structure
Labcorp's leadership team includes the CEO, CFO, and other key executives responsible for overseeing the company's strategic direction and operations. The organizational structure is divisional, with separate units for diagnostics and drug development.
Top Products and Market Share
Key Offerings
- Routine Clinical Testing: Includes blood tests, urinalysis, and other common diagnostic tests. Competitors include Quest Diagnostics, Mayo Clinic Laboratories. Market share difficult to precisely determine due to fragmentation, but Labcorp and Quest are major players.
- Specialty and Esoteric Testing: Covers genetic testing, cancer diagnostics, and other advanced assays. Competitors include Mayo Clinic Laboratories, ARUP Laboratories. Labcorp and Quest share a significant portion of this market.
- Drug Development Services: Encompasses central lab services, bioanalytical testing, and clinical trial management. Competitors include IQVIA, PPD, and Syneos Health. Labcorp has a substantial market presence in central lab services.
Market Dynamics
Industry Overview
The diagnostic testing industry is driven by an aging population, increasing prevalence of chronic diseases, and advancements in technology. The drug development services industry is fueled by pharmaceutical and biotechnology companies' need to outsource research and development activities.
Positioning
Labcorp is a leading player in both the diagnostic testing and drug development services industries, with a strong reputation for quality, innovation, and customer service. Its competitive advantages include its extensive network of laboratories, its broad range of testing services, and its expertise in clinical trial management.
Total Addressable Market (TAM)
The global clinical laboratory services market is estimated to be in the hundreds of billions of dollars. Labcorp is well positioned to capture a significant share of this TAM through its diverse service offerings and global reach.
Upturn SWOT Analysis
Strengths
- Large and established network of laboratories
- Broad range of testing services
- Strong brand reputation
- Extensive experience in clinical trial management
- Solid financial performance
Weaknesses
- Exposure to reimbursement pressures
- Dependence on acquisitions for growth
- Highly competitive market
- Regulatory risks
- Operational complexities
Opportunities
- Expansion into emerging markets
- Development of new and innovative testing services
- Increased outsourcing of drug development activities
- Growing demand for personalized medicine
- Strategic partnerships and acquisitions
Threats
- Increased competition from other clinical laboratories and CROs
- Reduced reimbursement rates from government and private payers
- Technological advancements that could disrupt the market
- Economic downturns
- Adverse regulatory changes
Competitors and Market Share
Key Competitors
- QDEL
- DGX
- HLTH
Competitive Landscape
Labcorp's competitive advantages include its size, scale, and comprehensive service offerings. Disadvantages may include slower decision-making compared to smaller, more nimble competitors.
Major Acquisitions
Personal Genome Diagnostics (PGDx)
- Year: 2022
- Acquisition Price (USD millions): 450
- Strategic Rationale: Expanded Labcorp's oncology testing capabilities and strengthened its position in the growing market for personalized medicine.
Growth Trajectory and Initiatives
Historical Growth: Discuss Laboratory Corporation of America Holdings's growth trends over the past years.
Future Projections: Provide projections for Laboratory Corporation of America Holdings's future growth based on analyst estimates.
Recent Initiatives: Highlight recent strategic initiatives undertaken by Laboratory Corporation of America Holdings.
Summary
Labcorp is a leading life sciences company with a strong position in both diagnostic testing and drug development services. Its large scale, comprehensive services, and established network are key strengths. However, it faces competition, reimbursement pressures, and regulatory risks. The company's strategic acquisitions and expansion into emerging markets position it for continued growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC), Market Research Reports, Analyst Estimates, Press Releases
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly, so it is essential to conduct thorough due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Laboratory Corporation of America Holdings
Exchange NYSE | Headquaters Burlington, NC, United States | ||
IPO Launch date 1990-03-29 | President, CEO & Chairman Mr. Adam H. Schechter | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 70000 | Website https://www.labcorp.com |
Full time employees 70000 | Website https://www.labcorp.com | ||
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governments, physician, large provider organizations, other healthcare providers, hospitals and health systems, patients and consumers, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.